In CHOL, we revealed that XPO1 inhibitor KPT‐330 triggered the nuclear accumulation of the p53 protein and significantly disrupted the proliferation of cholangiocarcinoma cells. The gene discussed is TP53; the disease is cholangiocarcinoma.